CHRS
Income statement / Annual
Last year (2024), Coherus BioSciences, Inc.'s total revenue was $266.96 M,
an increase of 3.78% from the previous year.
In 2024, Coherus BioSciences, Inc.'s net income was $28.51 M.
See Coherus BioSciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$266.96 M |
$257.24 M |
$211.04 M |
$326.55 M |
$475.82 M |
$356.07 M |
$1.56 M |
$1.56 M |
$190.11 M |
$30.04 M |
| Cost of Revenue |
$0.00
|
$162.78 M
|
$70.08 M
|
$57.59 M
|
$37.67 M
|
$17.08 M
|
$3.24 M
|
$160.53 M
|
$254.44 M
|
$212.68 M
|
| Gross Profit |
$266.96 M
|
$94.46 M
|
$140.96 M
|
$268.96 M
|
$438.16 M
|
$338.99 M
|
-$1.68 M
|
-$158.98 M
|
-$64.33 M
|
-$182.64 M
|
| Gross Profit Ratio |
1
|
0.37
|
0.67
|
0.82
|
0.92
|
0.95
|
-1.08
|
-102.17
|
-0.34
|
-6.08
|
| Research and Development Expenses |
$93.34 M
|
$109.44 M
|
$199.36 M
|
$363.11 M
|
$142.76 M
|
$94.19 M
|
$110.24 M
|
$162.39 M
|
$254.44 M
|
$213.06 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$187.98 M
|
$161.01 M
|
$135.28 M
|
$132.54 M
|
$94.18 M
|
$71.30 M
|
$51.60 M
|
$36.05 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$10.50 M
|
$8.70 M
|
$3.80 M
|
$4.50 M
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$167.74 M
|
$185.62 M
|
$198.48 M
|
$169.71 M
|
$139.08 M
|
$137.04 M
|
$94.18 M
|
$71.30 M
|
$51.60 M
|
$36.05 M
|
| Other Expenses |
$0.00
|
$0.00
|
$3.82 M
|
-$283,000.00
|
$554,000.00
|
$2.61 M
|
$4.69 M
|
$3.40 M
|
-$3.88 M
|
-$4.84 M
|
| Operating Expenses |
$261.07 M
|
$301.45 M
|
$397.84 M
|
$532.82 M
|
$281.84 M
|
$231.23 M
|
$204.42 M
|
$233.69 M
|
$306.04 M
|
$249.11 M
|
| Cost And Expenses |
$378.63 M
|
$460.44 M
|
$467.92 M
|
$590.41 M
|
$319.51 M
|
$248.30 M
|
$204.42 M
|
$233.69 M
|
$306.04 M
|
$249.11 M
|
| Interest Income |
$0.00
|
$0.00
|
$30.57 M
|
$21.56 M
|
$20.57 M
|
$16.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$27.16 M
|
$40.54 M
|
$32.47 M
|
$22.96 M
|
$21.17 M
|
$17.60 M
|
$9.68 M
|
$9.55 M
|
$7.98 M
|
$33,000.00
|
| Depreciation & Amortization |
$0.00
|
$3.79 M
|
$3.70 M
|
$5.66 M
|
$4.97 M
|
$3.26 M
|
$3.24 M
|
$3.40 M
|
$3.00 M
|
$1.87 M
|
| EBITDA |
-$111.67 M |
-$193.94 M |
-$255.58 M |
-$260.69 M |
$161.84 M |
$111.03 M |
-$204.42 M |
-$225.34 M |
-$116.81 M |
-$222.04 M |
| EBITDA Ratio |
-0.42
|
-0.75
|
-1.2
|
-0.81
|
0.33
|
0.31
|
-128.36
|
-147
|
-0.63
|
-7.45
|
| Operating Income Ratio |
-0.42
|
-0.79
|
-1.22
|
-0.81
|
0.33
|
0.3
|
-131.37
|
-149.19
|
-0.61
|
-7.29
|
| Total Other Income/Expenses Net |
$140.17 M
|
-$35.07 M
|
-$34.87 M
|
-$23.24 M
|
-$20.61 M
|
-$14.99 M
|
-$4.99 M
|
-$6.15 M
|
-$11.86 M
|
-$4.87 M
|
| Income Before Tax |
$28.51 M
|
-$238.27 M
|
-$291.75 M
|
-$287.10 M
|
$135.71 M
|
$92.78 M
|
-$209.41 M
|
-$238.29 M
|
-$127.79 M
|
-$223.94 M
|
| Income Before Tax Ratio |
0.11
|
-0.93
|
-1.38
|
-0.88
|
0.29
|
0.26
|
-134.58
|
-153.14
|
-0.67
|
-7.45
|
| Income Tax Expense |
$0.00
|
-$380,000.00
|
$34.87 M
|
$19.22 M
|
$3.46 M
|
$2.94 M
|
$4.69 M
|
$9.44 M
|
$656,000.00
|
-$7.35 M
|
| Net Income |
$28.51 M
|
-$237.89 M
|
-$326.63 M
|
-$306.32 M
|
$132.24 M
|
$89.83 M
|
-$209.34 M
|
-$238.17 M
|
-$127.34 M
|
-$223.26 M
|
| Net Income Ratio |
0.11
|
-0.92
|
-1.55
|
-0.94
|
0.28
|
0.25
|
-134.54
|
-153.07
|
-0.67
|
-7.43
|
| EPS |
0.25 |
-2.53 |
-4.21 |
-4.06 |
1.85 |
1.29 |
-3.22 |
-4.48 |
-3.04 |
-6.01 |
| EPS Diluted |
0.25 |
-2.53 |
-4.21 |
-4.06 |
1.62 |
1.23 |
-3.22 |
-4.48 |
-3.04 |
-6.01 |
| Weighted Average Shares Out |
$114.55 M
|
$94.16 M
|
$77.63 M
|
$75.45 M
|
$71.41 M
|
$69.68 M
|
$65.01 M
|
$53.13 M
|
$41.91 M
|
$37.12 M
|
| Weighted Average Shares Out Diluted |
$114.83 M
|
$94.16 M
|
$77.63 M
|
$75.45 M
|
$83.49 M
|
$73.19 M
|
$65.03 M
|
$53.13 M
|
$41.91 M
|
$37.12 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
